{"filing":{"accession_number":"0001437749-26-030492","cik":"0001719406","ticker":"NRXPW","company_name":"NRX Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-15","primary_document":"nrxp20260915_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1719406/000143774926030492/nrxp20260915_8k.htm"},"events":[{"id":33730,"run_id":31030,"accession_number":"0001437749-26-030492","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"NRx Pharmaceuticals received FDA notification that its ANDA amendment for preservative-free ketamine (NRX-100) was reclassified from a Major Amendment to a Minor Amendment, with the GDUFA goal date revised to November 10, 2026. This is a material regulatory milestone that accelerates the approval timeline for a strategic drug-shortage product, directly affecting the company's development pathway and commercial prospects. While not fitting a specific named category, this is clearly an operational/regulatory event material to investors assessing the company's pipeline progress.","company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXPW","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":[{"id":37249,"accession_number":"0001437749-26-030492","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"NRx Pharmaceuticals received FDA notification that its ANDA amendment for preservative-free ketamine (NRX-100) was reclassified from a Major Amendment to a Minor Amendment, with the GDUFA goal date revised to November 10, 2026. This is a material regulatory milestone that accelerates the approval timeline for a strategic drug-shortage product, directly affecting the company's development pathway and commercial prospects. While not fitting a specific named category, this is clearly an operational/regulatory event material to investors assessing the company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-16T10:03:51.924219+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37249,"accession_number":"0001437749-26-030492","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"NRx Pharmaceuticals received FDA notification that its ANDA amendment for preservative-free ketamine (NRX-100) was reclassified from a Major Amendment to a Minor Amendment, with the GDUFA goal date revised to November 10, 2026. This is a material regulatory milestone that accelerates the approval timeline for a strategic drug-shortage product, directly affecting the company's development pathway and commercial prospects. While not fitting a specific named category, this is clearly an operational/regulatory event material to investors assessing the company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-16T10:03:51.924219+00:00","company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXPW","filing_date":"2026-09-15"}]}